ViaDerma Inc (VDRM)

[Grolden]

VDRM DD Compiliation. This is just a start theres a ton of DD on this on!








http://topics.nytimes.com/top/news/business/companies/murals-by-maurice-inc/index.html

“TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.”

TetraStem Results & Case Studies (need to look its amazing)

1 Example


http://viadermalicensing.com/img/ViaDermaCaseStudies.pdf
https://plsdrugs.com/component/content/category/2-uncategorised

Recent news

Mar 02, 2015
OTC Disclosure & News Service

Quote:
LOS ANGELES, March 2, 2015 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTCQB:VDRM) (The Company), a specialty pharmaceutical company devoted to bringing new products to market, is excited to start participating in test trials with a major Food and Drug Administration (FDA) approved toenail fungus treatment.

Onychomycosis is a fungal infection of the toenails or fingernails that may involve any part of the nail itself. This infection can cause pain, distress, and deformity that could produce serious physical and occupational restrictions, as well as affect quality of life.

Recently registered as a medication by the FDA, TetraStem is a liquid tetracycline-based antibiotic that is designed to treat cuts, scrapes, and burns. TetraStem has also shown success in treating diabetic foot sores, acne, and fighting methicillin-resistant Staphylococcus aureus (MRSA)infections.

ViaDerma introduced an upcoming trial, slotted to take place this coming spring, that will feature their lead product, TetraStem, against a well-known prescription treatment for Onychomycosis. Trials will begin taking place with patients receiving both treatments at 90-day, six months, nine months, and one year lapses of time. Previously used as an off-label treatment for Onychomycosis with proven results, ViaDerma believes that TetraStem will serve as a possible more effective and more affordable option than other leading brands.

TetraStem has been seen in private off-label practice to hold an 86% success rate after only 12 weeks of use. In comparison, the competition has only seen an 18% success rate, requiring 48 weeks of patient use. Not only are these differences staggering, but to add to that, a bottle of TetraStem retails for only $39.99, whereas the same size has been sold for more than $500 through other brands.

"We are excited about expanding our lead product to treat an ever-expanding list of needs of patients who may be looking for new treatment options," commented Dr. Christopher Otiko, CEO of ViaDerma. "I believe, with high hopes, that these trials will produce the results that we, as a company, have been awaiting."

ViaDerma, Inc. Announces Strategic Partnership With The Brewer Group

Collaboration will help promote ViaDerma's innovative technology and expand the domestic and international demand for its cutting-edge pharmaceutical rapid delivery system
PR Newswire

MINNEAPOLIS, and BEVERLY HILLS, Calif., Aug. 5, 2014

MINNEAPOLIS, and BEVERLY HILLS, Calif., Aug. 5, 2014 /PRNewswire/ -- ViaDerma, Inc. (OTCQB: VDRM), a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research and development, and The Brewer Group, Inc. (TBG), a diversified global investment advisory firm, today announced a new strategic partnership. TBG will expand ViaDerma's business development and marketing efforts at home and abroad to grow interest in ViaDerma's patent-pending pharmaceutical delivery system, which allows for rapid transdermal transfer of active ingredients and immediate relief of symptoms.

BREWER GROUP IS HUUUUGE!
http://www.thebrewergroup.com/

SS
A/S 150,000,000
O/S 73,112,116
Float 10,428,638

FDA approved
http://www.drugs.com/otc/tetrastem.html


Looks like were working with Phillips Company

On January 31, 2014, the Company purchased an exclusive license on the patent pending technology from Dr. Howard Phillips represented by US Patent #20130190274. Pursuant to the agreement, the Company maintains their exclusive license to the technology so long as it makes a one-time inventory purchase of at least $20,000 on or before March 31, 2014 and pays Dr. Phillips a monthly royalty of $.25 for every product sold or $1,000 monthly, whichever is greater, beginning in June 2014. The Company has already completed the initial inventory purchase required under the agreement.

http://www.google.com/patents/US20120070390


Phillips Company has many FDA approved drugs such as Tetrastem, Tetra ABC...etc.

http://www.phillipscompany.4t.com/

Our CEO

For the past five years Dr. Chris Ayo Otiko has worked in the biotechnology field performing research and development. His Master of Science background in Biochemistry, along with his pioneering clinical work as a Podiatric Surgeon, allowed Dr. Otiko to develop a new topical antibiotic product that won Drug Store News Best New Product award in 2012.
Dr. Otiko also personally developed and supervised the human clinical trials that resulted in the founding of ViaDerma, Inc., in 2014 where he now serves as Chairman of the Board and CEO. The ViaDerma products feature a ground breaking delivery system that allows for rapid mass transfer of a diverse range of pharmaceuticals through the skin and directly into the affected body part to provide immediate localized therapy. Prior to founding ViaDerma, Dr. Otiko practiced medicine in his specialty surgical field and built / sold several medical related companies in Southern California. Dr. Otiko received a Master Degree of Science Degree in Biochemistry from Oklahoma State in 1993 and a Doctorate from the California College of Podiatric Medicine, San Francisco (now called California School of Podiatric Medicine at Samuel Merritt University) in 1997.

https://www.linkedin.com/pub/chris-ayo-otiko/5/84b/802

http://www.yelp.com/biz/chris-otiko-reseda

ViaDerma, Inc. has products in development in the following fields; topical antibiotics (TetraStem), topical anti-viral product (Viralcur) for genital herpes, anti-fungal products for onychomycocis (OnyPro), hair loss prevention product (HairGain), skin cancer therapies (Cantrile), and a topical stem cell therapy product(TetraStem Plus). The products have a patent pending delivery system technology that allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy. The technology is patent-pending, based on the work of inventor Dr. Howard Phillips. The company also has an additional layer of protection via its Trade Secret Formulation System utilized in the manufacture of all the products.

Viaderma Inc. is a pharmaceutical company committed to bringing new products to the pharmaceutical industry through research and development. The Company licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. It has products in development in the following fields: topical antibiotics (TetraStem), topical anti-viral product (Viralcur) for genital herpes, anti-fungal products for onychomycocis (OnyPro), hair loss prevention product (HairGain), skin cancer therapies (Cantrile), and a topical stem cell therapy product (TetraStem Plus). The Company has used the dual-carrier technology to develop the following products: ACNECLIR/ACNEEN; ACNECYCLINE; ADVANCED JELLYFISH STING KIT; DERMONEEN; ECODERM; IVYMED; STAPHWASH PLUS; STINGMED; TETRA-ABC; TETRA-STEM; VENOMX.

I called the President Chris today (818-836-2475) and he said that nvsos as well as OTCmarkets will be updated shortly. I also called the number on otcmarkets and they answered "Viaderma".

http://www.viadermalicensing.com/